Three-Dimensional Imaging for Facial Vitiligo: Results from a Phase 2 Randomized Controlled Trial Investigating Upadacitinib in Patients with Vitiligo

January 2026 in “ Journal of Investigative Dermatology ”

Anand K. Ganesan, Ezzedine Khaled, Sameh Hanna, Mehdi Rashighi, Julien Sénéschal, Sandra Goss, Bethanee J. Schlosser, X. Hu, Tiancheng He, Michelle Crouthamel, Heidi S. Camp, Thierry Passeron

upadacitinib vitiligo 3D imaging skin pigmentation

TLDR 3D imaging effectively tracks skin changes in vitiligo treatment.

A phase 2 randomized controlled trial investigated the use of upadacitinib (UPA) in patients with vitiligo, utilizing 3D imaging to objectively evaluate changes in facial vitiligo. The study demonstrated that 3D imaging could effectively capture and quantify changes in skin pigmentation, providing a reliable method for assessing treatment outcomes. This approach offers a promising tool for clinicians to monitor the efficacy of vitiligo treatments, potentially improving patient management and treatment strategies.

View this study on jidonline.org →

Discuss this study in the Community →

Similar Research

5 / 163 results

research 8th International Conference: Interdisciplinary Aspects of Diseases of the Skin and Mucous Membranes, March 11-12, 2022

January 2022 in “Dermatology Review”

Higher IL-31 levels are linked to worse itching in chronic kidney disease patients.

research The Role of Janus Kinases in the Treatment of Autoimmune Skin Diseases

1 citations , February 2021 in “Farmacja Polska”

Janus kinase inhibitors show promise in treating autoimmune skin diseases.

research SOCS1 and SOCS3 as key checkpoint molecules in the immune responses associated to skin inflammation and malignant transformation

26 citations , June 2024 in “Frontiers in Immunology”

SOCS1 and SOCS3 help control skin inflammation and are important for developing treatments for skin diseases.

research Off-Label Uses of Abrocitinib: Review of Emerging Therapeutic Applications Beyond Atopic Dermatitis

10 citations , September 2024 in “Life”

Abrocitinib shows promise for treating various skin conditions beyond atopic dermatitis.

research The JAK/STAT Signaling Pathway: From Bench to Clinic

489 citations , November 2021 in “Signal Transduction and Targeted Therapy”

The JAK/STAT pathway is important in cell processes and disease, and JAK inhibitors are promising for treating related conditions.